Close
  Indian J Med Microbiol
 

Figure 1: A comparison of the changes in the macular thickness in treated and untreated eyes of the same patients, before (baseline) and at 4 weeks after the intravitreal bevacizumab and ranibizumab injections. Note that a statistically significant decrease in the central subfield macular thickness was seen with the bevacizumab administration, but not with the ranibizumab. ìm: Microns

Figure 1: A comparison of the changes in the macular thickness in treated and untreated eyes of the same patients, before (baseline) and at 4 weeks after the intravitreal bevacizumab and ranibizumab injections. Note that a statistically significant decrease in the central subfield macular thickness was seen with the bevacizumab administration, but not with the ranibizumab. ìm: Microns